Akorn, Inc.

246 articles with Akorn, Inc.

• 

  BioSpace Movers and Shakers: March 22

  3/22/2019

  Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
• 

  FDA Warning Letters: An Overview of 2019’s Letters So Far

  3/13/2019

  The FDA issues Warning Letters to biopharma, medical device and food companies when they find that a manufacturer has significantly violated FDA regulations. As of March 4, the agency issued 45 Warning Letters this year.
• 

  Allergan Backs off From $200 Million Plant Expansion in Waco, Texas

  11/6/2018

  Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”
• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• Akorn Comments on Delaware Chancery Court Ruling

  10/1/2018

  Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to the ruling by the Delaware Chancery Court on the complaint filed by Akorn against Fresenius Kabi AG

• 

  Allergan’s Good News Doesn’t Quite Outweigh the Bad

  7/23/2018

  Despite positive Phase III clinical trial data for Allergan’s age-related macular degeneration drug, investors weren’t as positive about it.
• 

  Fresenius Walks Away from Agreement: Shares of Akorn Plummet

  4/23/2018

  Almost one year to the day after Fresenius plunked down $4.3 billion to acquire Illinois-based Akorn Pharmaceuticals, the German company announced it was walking away from the deal.

• Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement

  4/23/2018

  Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement:

• 

  Drugs That Are Likely to Fall Off the Patent Cliff This Year

  4/5/2018

  If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.

• AKORN, INC. INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Akorn, Inc.

  3/21/2018

  The law firm Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the publicly traded securities of Akorn, Inc. between March 1, 2017 and February 26, 2018.

• 

  Completion of Akorn Takeover Expected in Early 2018

  12/20/2017

  Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.

• Akorn Shareholders Vote To Approve Merger Agreement With Fresenius Kabi AG

  7/20/2017

• U.S. Generic Drugmaker Akorn Surges On Reports Fresenius SE Is Interested

  4/10/2017

• Akorn, Inc. Receives FDA Approval For Ephedrine Sulfate Injection, USP

  3/2/2017

• Akorn, Inc. Receives Approval For Mycophenolate Mofetil For Injection, USP

  3/1/2017

• Akorn, Inc. Provides Fourth Quarter And Full Year 2016 Results And Outlines Full Year 2017 Guidance

  3/1/2017

• Akorn, Inc. To Report Fourth Quarter And Full Year 2016 Results

  2/6/2017

• Akorn, Inc. Announces Completion Of FDA Re-Inspection Of Decatur Facility

  12/12/2016

• Akorn, Inc. Launches Ibuprofen Oral Suspension

  11/29/2016

• Akorn, Inc. Invalidates Durezol Patent Via Inter Partes Review Proceeding

  11/29/2016